Literature DB >> 9186550

Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells.

D A Fishman1, L M Bafetti, M S Stack.   

Abstract

Metastatic dissemination of epithelial ovarian carcinoma occurs primarily through exfoliation of cells from the primary tumor, with subsequent implantation, invasion, and growth throughout the organs within the peritoneal cavity. Previous studies have suggested a role for matrix metalloproteinases (MMPs), particularly MMP-2, in ovarian cancer invasion and metastasis. To characterize further the role of MMPs and their inhibitors in ovarian carcinoma, in this study the production and activation of MMPs by short-term primary cultures of human ovarian epithelial carcinoma cells were analyzed. We report that MMP-2 is the predominant gelatinolytic MMP secreted by primary ovarian cancer cells derived from both ovarian tumors and ascites fluid. Furthermore, zymographic analysis demonstrated that MMP-2 is present in conditioned media in both the latent and activated forms, indicating that primary ovarian cancer cells catalyze proMMP-2 activation. Presence of a proMMP-2 activator was confirmed by immunohistochemistry and immunoprecipitation studies which found membrane-type 1 MMP (MT1-MMP) in the membranes of unstimulated cells and levels of both MT1-MMP and tissue inhibitor of metalloproteinases-2 (TIMP-2) were enhanced by culturing cells in the presence of concanavalin A. In addition, interaction of MMP-2 with the ovarian carcinoma cell surface resulted in a 2.5- to 5-fold increase in invasiveness. These data suggest that MT1-MMP-catalyzed activation of proMMP-2 may play a physiologic role in intraperitoneal invasion of ovarian carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9186550

Source DB:  PubMed          Journal:  Invasion Metastasis        ISSN: 0251-1789


  15 in total

1.  Reduced NO signaling during pregnancy attenuates outward uterine artery remodeling by altering MMP expression and collagen and elastin deposition.

Authors:  Sarah A Hale; Lindsey Weger; Maurizio Mandala; George Osol
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-08-19       Impact factor: 4.733

2.  Stress hormone-mediated invasion of ovarian cancer cells.

Authors:  Anil K Sood; Robert Bhatty; Aparna A Kamat; Charles N Landen; Liz Han; Premal H Thaker; Yang Li; David M Gershenson; Susan Lutgendorf; Steven W Cole
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

3.  Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment.

Authors:  D A Fishman; A Kearns; S Larsh; J J Enghild; M S Stack
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

4.  High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma.

Authors:  B Davidson; I Goldberg; W H Gotlieb; J Kopolovic; G Ben-Baruch; J M Nesland; A Berner; M Bryne; R Reich
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

5.  Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas.

Authors:  N Johansson; M Vaalamo; S Grénman; S Hietanen; P Klemi; U Saarialho-Kere; V M Kähäri
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

Review 6.  Ovarian cancer: involvement of the matrix metalloproteinases.

Authors:  Linah Al-Alem; Thomas E Curry
Journal:  Reproduction       Date:  2015-04-27       Impact factor: 3.906

Review 7.  Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development.

Authors:  Lidiya S Orlichenko; Derek C Radisky
Journal:  Clin Exp Metastasis       Date:  2008-02-20       Impact factor: 5.150

Review 8.  Activated epidermal growth factor receptor in ovarian cancer.

Authors:  Laurie G Hudson; Reema Zeineldin; Melina Silberberg; M Sharon Stack
Journal:  Cancer Treat Res       Date:  2009

9.  The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.

Authors:  Aparna A Kamat; Mavis Fletcher; Lynn M Gruman; Peter Mueller; Adriana Lopez; Charles N Landen; Liz Han; David M Gershenson; Anil K Sood
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

Review 10.  Biologic directed therapies in gynecologic oncology.

Authors:  John H Farley; Michael J Birrer
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.